Association of time in range with lower extremity atherosclerotic disease in type 2 diabetes mellitus: a prospective cohort study

被引：10
作者：
Wang, Yaxin [1 ,2 ,3 ,4 ]
Lu, Jingyi [1 ,2 ,3 ,4 ]
Shen, Yun [1 ,2 ,3 ,4 ]
Ni, Jiaying [1 ,2 ,3 ,4 ]
Zhang, Lei [1 ,2 ,3 ,4 ]
Lu, Wei [1 ,2 ,3 ,4 ]
Zhu, Wei [1 ,2 ,3 ,4 ]
Bao, Yuqian [1 ,2 ,3 ,4 ]
Zhou, Jian [1 ,2 ,3 ,4 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Endocrinol & Metab, Sch Med, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China
[2] Shanghai Clin Ctr Diabet, Shanghai 200233, Peoples R China
[3] Shanghai Diabet Inst, Shanghai 200233, Peoples R China
[4] Shanghai Key Lab Diabet Mellitus, Shanghai 200233, Peoples R China
来源：
ENDOCRINE | 2022年 / 76卷 / 03期
关键词：
Time in range; Lower extremity atherosclerotic disease; Type; 2; diabetes; Cohort study; GLUCOSE-SENSING TECHNOLOGY; GLYCEMIC CONTROL; MANAGEMENT; COMPLICATIONS; MULTICENTER; GUIDELINE; UPDATE; ADULTS;
D O I：
10.1007/s12020-022-03038-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose Time in range (TIR) has surfaced as a key continuous glucose monitoring (CGM)-derived metric, which was linked to diabetes-related outcomes. We aimed to investigate the association of TIR with the risk of lower extremity atherosclerotic disease (LEAD) among patients with type 2 diabetes. Methods A total of 1351 adult patients with type 2 diabetes were prospectively recruited from a single center in Shanghai, China. TIR was obtained from CGM data at baseline. LEAD was measured with color Doppler ultrasonography. Cox proportion hazard regression analysis was used to assess the association between TIR and the risk of incident/ progressive LEAD. Results During a median follow-up of 7.4 years, 450 participants developed incident/progressive LEAD. The multivariable-adjusted hazard ratios (HRs) for incident/progressive LEAD across different levels of TIR ( > 85%, 71-85%, 51-70%, and <= 50%) were 1.00, 1.15 (95% confidence interval [CI] 0.87-1.52), 1.37 (95% CI 1.04-1.80) and 1.46 (95% CI 1.10-1.94) (P for trend = 0.004), respectively. With each 10% decrease in TIR, the multivariable-adjusted risk of incident/progressive LEAD increased by 7% (95% CI 1.02-1.11). Similar results were found in the association between TIR and incident LEAD as the secondary outcome (P for trend < 0.001). Conclusions The current study found an inverse association of TIR with the risk of LEAD among patients with type 2 diabetes.
引用
收藏
页码：593 / 600
页数：8
相关论文
共 32 条
[11]   Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus [J].
El Malahi, Anass ;
Van Elsen, Michiel ;
Charleer, Sara ;
Dirinck, Eveline ;
Ledeganck, Kristien ;
Keymeulen, Bart ;
Crenier, Laurent ;
Radermecker, Regis ;
Taes, Youri ;
Vercammen, Chris ;
Nobels, Frank ;
Mathieu, Chantal ;
Gillard, Pieter ;
De Block, Christophe .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02) :E570-E581
[12]   American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus [J].
Grunberger, George ;
Sherr, Jennifer ;
Allende, Myriam ;
Blevins, Thomas ;
Bode, Bruce ;
Handelsman, Yehuda ;
Hellman, Richard ;
Lajara, Rosemarie ;
Roberts, Victor Lawrence ;
Rodbard, David ;
Stec, Carla ;
Unger, Jeff .
ENDOCRINE PRACTICE, 2021, 27 (06) :505-537
[13]   Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes [J].
Guo, Qingyu ;
Zang, Pu ;
Xu, Shaoying ;
Song, Wenjing ;
Zhang, Zhen ;
Liu, Chunyan ;
Guo, Zhanhong ;
Chen, Jing ;
Lu, Bin ;
Gu, Ping ;
Shao, Jiaqing .
JOURNAL OF DIABETES RESEARCH, 2020, 2020
[14]   Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial [J].
Haak, Thomas ;
Hanaire, Helene ;
Ajjan, Ramzi ;
Hermanns, Norbert ;
Riveline, Jean-Pierre ;
Rayman, Gerry .
DIABETES THERAPY, 2017, 8 (01) :55-73
[15]   The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes [J].
He, Xingxing ;
Su, Jiaorong ;
Ma, Xiaojing ;
Lu, Wei ;
Zhu, Wei ;
Wang, Yufei ;
Bao, Yuqian ;
Zhou, Jian .
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[16]   The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes [J].
Kim, Min Young ;
Kim, Gyuri ;
Park, Ji Yun ;
Choi, Min Sun ;
Jun, Ji Eun ;
Lee, You-Bin ;
Jin, Sang-Man ;
Hur, Kyu Yeon ;
Kim, Jae Hyeon .
DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (06) :434-442
[17]   Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies [J].
Kristensen, Karl ;
Ogge, Linda E. ;
Sengpiel, Verena ;
Kjolhede, Karin ;
Dotevall, Annika ;
Elfvin, Anders ;
Knop, Filip K. ;
Wiberg, Nana ;
Katsarou, Anastasia ;
Shaat, Nael ;
Kristensen, Lars ;
Berntorp, Kerstin .
DIABETOLOGIA, 2019, 62 (07) :1143-1153
[18]   A New Equation to Estimate Glomerular Filtration Rate [J].
Levey, Andrew S. ;
Stevens, Lesley A. ;
Schmid, Christopher H. ;
Zhang, Yaping ;
Castro, Alejandro F., III ;
Feldman, Harold I. ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Greene, Tom ;
Coresh, Josef .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (09) :604-612
[19]   Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: A preliminary study [J].
Lu, Jingyi ;
Ma, Xiaojing ;
Zhang, Lei ;
Mo, Yifei ;
Lu, Wei ;
Zhu, Wei ;
Bao, Yuqian ;
Jia, Weiping ;
Zhou, Jian .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 161
[20]   Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes [J].
Lu, Jingyi ;
Ma, Xiaojing ;
Shen, Yun ;
Wu, Qiang ;
Wang, Ren ;
Zhang, Lei ;
Mo, Yifei ;
Lu, Wei ;
Zhu, Wei ;
Bao, Yuqian ;
Vigersky, Robert A. ;
Jia, Weiping ;
Zhou, Jian .
DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (02) :72-78
1234